
3. Dezember 2024Deals & Cases
Kellerhals Carrard Advises on the Sale of Baccinex S.A. to Adragos Pharma
On 21 November 2024, Baccinex S.A., a Swiss-based aseptic fill-finish manufacturer located in Courroux, Jura, was acquired by Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany. Baccinex S.A. has over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex S.A. specializes in clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients. Kellerhals Carrard advised the seller on all legal aspects of the transaction. The team was led by Nicolas Mosimann (Partner M&A) and further included Marco Sibold (Partner Tax), Kevin MacCabe (Senior Associate M&A) and Sebastian Müller (Associate M&A). Kontakte![]() Dr. Kevin MacCabeTel. +41 58 200 30 75 Fax +41 58 200 30 11 kevin.maccabe@kellerhals-carrard.ch ![]() Dr. Nicolas MosimannTel. +41 58 200 30 49 Fax +41 58 200 30 11 nicolas.mosimann@kellerhals-carrard.ch ![]() Marco SiboldTel. +41 58 200 30 54 Fax +41 58 200 30 11 marco.sibold@kellerhals-carrard.ch ![]() Sebastian T. P. MüllerTel. +41 58 200 37 30 Fax +41 58 200 30 11 sebastian.mueller@kellerhals-carrard.ch |